中教数据库 > World Journal of Gastrointestinal Oncology > 文章详情

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers

更新时间:2023-05-28

【摘要】BACKGROUND Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers(BTC).There is no established second-line therapy,and retrospective reviews report median progression-free survival(PFS) less than3 mo on second-line therapy.5-Fluorouracil plus irinotecan(FOLFIRI) is a commonly used regimen in patients with BTC who have progressed on gemcitabine plus platinum,though there is a paucity of data regarding its efficacy in this population.AIM To assess the efficacy of FOLFIRI in patients with biliary tract cancers.METHODS We retrospectively identified patients with advanced BTC who were treated with FOLFIRI at MD Anderson,University of Michigan and Mayo Clinic in Jacksonville.Data were collected on patient demographics,BTC subtype,response per RECIST v1.1,progression and survival.RESULTS Ninety-eight patients were included of which 74(75%) had metastatic and 24(25%) had locally advanced disease at the time of treatment with FOLFIRI.The median age was 60(range,22-86) years.The number of patients with extrahepatic cholangiocarcinoma,gall bladder cancer and intrahepatic cholangiocarcinoma were 10,17 and 71,respectively.FOLFIRI was used as 1 st,2 nd,3 rd or 4 th – Nth lines in 8,50,36 and 4 patients,respectively.Median duration on FOLFIRI in the entire cohort was 2.2(range,0.5-8.4) mo.The median PFS and overall survival were 2.4(95% confidence interval(CI):1.7-3.1) and 6.6(95%CI:4.7-8.4) mo,respectively.Median PFS for patients treated with FOLFIRI in 1 st,2 nd,3 rd or 4 th – Nth lines were3.1,2.5,2.3 and 1.5 mo,respectively.Eighteen patients received concurrent bevacizumab(n = 13) or EGFR-targeted therapy(n = 5) with FOLFIRI,with a median PFS of 2.7 mo(95%CI:1.7-5.1).CONCLUSION In this largest multi-institution retrospective review of 98 patients with BTC treated with FOLFIRI,efficacy appears to be modest with outcomes similar to other cytotoxic chemotherapy regimens.

【关键词】

228 2页 免费

发表评论

登录后发表评论 (已发布 0条)

点亮你的头像 秀出你的观点

0/500
以上留言仅代表用户个人观点,不代表中教立场
相关文献

推荐期刊

Copyright © 2013-2016 ZJHJ Corporation,All Rights Reserved

京ICP备2021021570号-13

京公网安备 11011102000866号